De 2014 fluoroquinolones target dna gyrase and topoisomerase iv with varying efficiency in different bacteria and inhibit their control of supercoiling within the cell, resulting in. In this review, the current knowledge on the mode of action of quinolones, how they kill bacteria and known pathways to resistance will be discussed. Moreover, we will review the current literature on sublethal quinolone exposure leading to resistance to quinolone and non. Quinolones dually target dna gyrase and topoisomerase iv binding to specific domains and conformations so as to block dna strand passage catalysis and stabilize dnaenzyme. De 2020 the fluoroquinolones are a family of broad spectrum, systemic antibacterial agents that have been used widely as therapy of respiratory and urinary tract infections.
De 2024 since the introduction of quinolone and fluoroquinolone antibiotics to treat bacterial infections in the 1960s, there has been a pronounced increase in the number of. The newer fluoroquinolones are a major advance in antimicrobial chemotherapy. They inhibit the supercoiling activity of the dna gyrase enzyme, thus exerting their antibacterial action on dna.